ClinicalTrials.gov record
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

ClinicalTrials.gov ID: NCT02016924

Public ClinicalTrials.gov record NCT02016924. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants

Study identification

NCT ID
NCT02016924
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Gilead Sciences
Industry
Enrollment
133 participants

Conditions and interventions

Interventions

  • ATV Drug
  • BR Drug
  • Cobicistat Drug
  • Cobicistat TOS Drug
  • DRV Drug
  • F/TAF Drug
  • F/TAF TOS Drug
  • LPV/r Drug
  • Third Unboosted Drug Drug

Drug

Eligibility (public fields only)

Age range
4 Weeks to 17 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 15, 2014
Primary completion
Jun 12, 2025
Completion
Feb 28, 2027
Last update posted
Apr 20, 2026

2014 – 2027

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Pediatric Infectious Disease Associates Long Beach California 90806
Peter Morton Medical Building Los Angeles California 90095
University of Colorado Denver Aurora Colorado 80045
The George Washington University Washington D.C. District of Columbia 20010
University of South Florida Tampa Florida 33606
St. Jude Children's Research Hospital Memphis Tennessee 38105
University of Texas Health Science Center of Houston Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02016924, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 20, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02016924 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →